Jump Financial LLC Invests $394,000 in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Jump Financial LLC acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 104,342 shares of the company's stock, valued at approximately $394,000. Jump Financial LLC owned about 0.15% of Amylyx Pharmaceuticals at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Blue Trust Inc. boosted its holdings in shares of Amylyx Pharmaceuticals by 232.1% during the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after acquiring an additional 4,883 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in Amylyx Pharmaceuticals in the fourth quarter worth approximately $45,000. RPO LLC bought a new stake in Amylyx Pharmaceuticals in the 4th quarter worth approximately $46,000. EntryPoint Capital LLC purchased a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $53,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Amylyx Pharmaceuticals during the 4th quarter valued at $56,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock traded up $0.18 during trading hours on Thursday, reaching $5.29. 292,985 shares of the company traded hands, compared to its average volume of 1,235,253. The firm has a 50-day moving average price of $3.79 and a 200 day moving average price of $4.19. The company has a market cap of $470.81 million, a P/E ratio of -1.38 and a beta of -0.53. Amylyx Pharmaceuticals, Inc. has a 12-month low of $1.58 and a 12-month high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million for the quarter. Sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Insider Buying and Selling

In related news, CFO James M. Frates sold 10,896 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $37,809.12. Following the transaction, the chief financial officer now directly owns 290,988 shares of the company's stock, valued at approximately $1,009,728.36. The trade was a 3.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joshua B. Cohen sold 11,851 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total transaction of $41,122.97. Following the sale, the chief executive officer now directly owns 3,201,247 shares of the company's stock, valued at approximately $11,108,327.09. This trade represents a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,509 shares of company stock valued at $222,586. Company insiders own 11.70% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on AMLX. Mizuho upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their price objective for the company from $3.00 to $7.00 in a research report on Monday, April 7th. HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $8.00.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.